Development and validation of a biomarker index for HCC treatment response
Jeff Liang,Po-Yi Li,Joshua Norman,Marie Lauzon,Yee Hui Yeo,Hirsh Trivedi,Walid S. Ayoub,Alexander Kuo,Marc L. Friedman,Kamya Sankar,Jun Gong,Arsen Osipov,Andrew Hendifar,Tsuyoshi Todo,Irene Kim,Georgios Voidonikolas,Todd V. Brennan,Steven A. Wisel,Justin Steggarda,Kambiz Kosari,Rola Saouaf,Nicholas Nissen,Francis Yao,Neil Mehta,Ju Dong Yang
DOI: https://doi.org/10.1097/hc9.0000000000000466
2024-06-19
Hepatology Communications
Abstract:Background: Serum AFP- L 3%, A FP, and D CP are useful biomarkers for HCC detection, but their utility in assessing treatment response remains unknown. We aim to evaluate the accuracy of a biomarker model in the detection of posttreatment viable tumors. Methods: For model derivation, recipients with HCC undergoing liver transplant from 2018 to 2022 who had biomarkers collected within 3 months before transplant were included. We developed a generalized linear model for detecting posttreatment viable tumors with the 3 biomarkers as covariates, which we termed the “LAD Score.” An independent cohort of 117 patients with HCC was used for external validation. Results: Among 205 recipients of transplant, 70.2% had evidence of viable tumor on explant. The median LAD score was higher among patients with viable versus nonviable tumors (1.06 vs. 0.465, p < 0.001). The LAD score had a sensitivity of 55.6% and a specificity of 85.1% at the cutoff of 0.927, which was more accurate than imaging for detecting posttreatment viable tumors (AUROC 0.736 vs. 0.643, respectively; p = 0.045). The superior performance of the LAD score over imaging is primarily driven by its greater accuracy in detecting tumors <2 cm in diameter (AUROC of the LAD score 0.721 vs. imaging 0.595, p = 0.02). In the validation data set, the LAD score had an AUROC of 0.832 (95% CI: 0.753, 0.911) with a sensitivity of 72.5% and a specificity of 89.4% at the cutoff of 0.927. Conclusions: Our findings suggest the utility of LAD score in treatment response assessment after locoregional therapy for HCC, particularly in detecting small tumors. A larger prospective study is in progress to validate its accuracy and evaluate its performance in recurrence monitoring.
gastroenterology & hepatology